13 02, 2024

Webinar – COST Action AtheroNET

2024-02-13T11:20:12+01:00February 13th, 2024|biomarker, biomarkers, exosomes, extracellular vesicle, microRNA, microRNA services, microRNAs, quality, sequencing, smallRNA|Comments Off on Webinar – COST Action AtheroNET

Looking forward to sharing our insights from 10+ years of extracellular microRNA (and recently long RNA as well) biomarker discovery and diagnostic test development with the COST Action AtheroNET group. Date: 19.02.2024 Time: 19:30 CET Registration Link: https://lnkd.in/dVDDYKcA Reach out to Matthias directly after his webinar and discuss our latest developments and how TAmiRNA’s  miND spike ins and small RNA sequencing service can assist your business!

26 01, 2024

TAmiRNA ‘2023 In Review’

2024-01-26T11:44:38+01:00January 26th, 2024|biomarker, biomarkers, exosomes, extracellular vesicle, ISO 13485, Liver disease, microRNA, microRNA services, microRNAs, quality, sequencing, smallRNA|Comments Off on TAmiRNA ‘2023 In Review’

One last look back at 2023 before we turn our attention to our goals for 2024: last year brought us progress in many areas, from the development of new laboratory and data analyses to the implementation of hepatomiR® in routine clinical diagnostics and the establishment of important partnerships. Our thanks go to the entire (growing) TAmiRNA team, and our customers and partners! We look forward to working together and to our joint successes in 2024!

17 01, 2024

Analysis of extracellular vesicle microRNA profiles reveals distinct blood and lymphatic endothelial cell origins

2024-01-17T11:03:50+01:00January 17th, 2024|biomarker, biomarkers, exosomes, extracellular vesicle, microRNA, microRNA services, microRNAs|Comments Off on Analysis of extracellular vesicle microRNA profiles reveals distinct blood and lymphatic endothelial cell origins

We want to draw your attention to the latest collaborative publication by TAmiRNA scientist Marianne Pultar: “Analysis of extracellular vesicle microRNA profiles reveals distinct blood and lymphatic endothelial cell origins” published in the Journal of Extracellular Biology. By applying TAmiRNA´s unique small RNA-seq and RNA-seq workflows, this study provides important insights into the secretory behavior of endothelial cell-derived extracellular vesicles (EVs) and their microRNA cargo. In future, these findings can support the identification and development of non-invasive and cell-type specific biomarkers in liquid biopsis. Click here to learn more about our EV service click here to read the paper

15 01, 2024

Circulating endothelial extracellular vesicle signatures correspond with ICU requirement

2024-01-15T10:16:16+01:00January 15th, 2024|biomarker, biomarkers, CoV-2, diagnose disease, exosomes, extracellular vesicle, microRNA services, microRNAs|Comments Off on Circulating endothelial extracellular vesicle signatures correspond with ICU requirement

We want to draw your attention to the latest publication in cooperation with TAmiRNA – “Circulating endothelial extracellular vesicle signatures correspond with ICU requirement: an exploratory study in COVID-19 patients” published in Intensive Care Medicine Experimental. Using TAmiRNA’s expertise in the field of EV characterization, we found that endothelial EVs and associated miRNAs could be promising candidates for the diagnosis of patients with COVID-19. Click here to learn more about this service click here to read the paper

22 11, 2023

TAmiRNA meets Japanese Pharma to present microRNA Biomarker Discovery Solutions

2023-11-22T11:22:16+01:00November 22nd, 2023|biomarker, biomarkers, exosomes, extracellular vesicle, microRNA, microRNA services, microRNAs, NGS, PCR testing service, SPI|Comments Off on TAmiRNA meets Japanese Pharma to present microRNA Biomarker Discovery Solutions

Matthias Hackl, CEO/CSO of TAmiRNA, visited Japan between November 11th and 18th to join Summit Pharmaceutical international to introduce TAmiRNA to 12 medium- and large-size pharmaceutical companies. Matthias presented information on microRNA and mRNA biomarker discovery in liquid biopsies using TAmiRNA´s unique miND® pipeline for absolute quantification of microRNAs. In addition, Matthias joined a seminar on “Manufacturing and omic-based characterization of extracellular vesicles as drug products” organized by the local partner Summit Pharmaceutical International. In his talk, Matthias explained to >70 representatives from Japanese Universities and Pharmaceutical industry TAmiRNA’s the advantages of full molecular characterization of exosomes and extracellular vesicles (EVs) to determine EV composition, consistency, and mode-of-action.

9 10, 2023

TAmiRNA at Extracellular Vesicles Forum

2023-10-09T11:28:13+02:00October 9th, 2023|biomarker, biomarkers, extracellular vesicle, microRNAs, NGS, smallRNA|Comments Off on TAmiRNA at Extracellular Vesicles Forum

TAmiRNA Scientific Consultant Magdalena Mecking is attending the Extracellular Vesicles Forum on Oct 10th – 11th in Cambridge. Stop by one of her posters and learn more about how TAmiRNA’s service may benefit your EV project! Reach out to Magdalena directly and discuss our latest developments and how TAmiRNA's  services can assist your business!

30 01, 2023

Plasma levels of platelet-enriched microRNAs change during antiplatelet therapy in healthy subjects

2023-03-10T08:28:49+01:00January 30th, 2023|biomarkers, diagnose disease, extracellular vesicle, microRNA, platelet-associated miRNAs, smallRNA, thrombomiR, treatment monitoring|Comments Off on Plasma levels of platelet-enriched microRNAs change during antiplatelet therapy in healthy subjects

We want to draw your attention to our most recent publication where we investigated platelet-enriched miRNAs (thrombomiRs) as suitable candidates for monitoring antiplatelet therapy. The study provides evidence that thrombomiRs are promising biomarker candidates for monitoring the extent of platelet inhibition. This could enable stratification of patients depending on their response to antiplatelet therapy and guide treatment decisions. click here to read the paper

Go to Top